YOLFTbeta
CalciMedica, Inc. Common Stock

CalciMedica, Inc. Common Stock

CALC · NASDAQ · Healthcare / Biotechnology

1.21USD-0.01 (-0.82%)

Price History

Full chart

Market Stats

Previous Close1.22
Open1.31
Day Range1.19 – 1.31
52-Week Range1.62 – 36.00
Volume30.70K
Market Cap11.95M
P/E (TTM)0.00
Forward P/E0.00
EPS-6.91
Dividend Yield0.00%
Beta1.01
50-Day Avg2.90
200-Day Avg7.44

About

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. A. Rachel Leheny Ph.D.
  • Employees15
  • Headquarters505 Coast Boulevard South, La Jolla, CA, United States, 92037, USA
  • Websitehttps://calcimedica.com

Leadership

  • Dr. A. Rachel Leheny Ph.D.CEO & Director · b. 1963
  • Mr. Eric W. RobertsChief Business Officer & Vice Chairman of the Board · b. 1964
  • Dr. Sudarshan Hebbar M.D.Chief Medical Officer · b. 1966
  • Mr. Michael J. Dunn B.A., M.B.A.President & COO · b. 1956
  • Dr. Anjana Rao Ph.D.Co-Founder and Scientific Advisor
  • Dr. Patrick Hogan Ph.D.Co-Founder and Scientific Advisor
  • Dr. Stefan Feske M.D.Co-Founder and Scientific Advisor
  • Dr. Kenneth A. Stauderman Ph.D.Co-Founder & Chief Scientific Officer · b. 1954
  • Mr. Stephen B. BardinChief Financial Officer · b. 1991
  • Mr. John M. Dunn J.D.General Counsel · b. 1952

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-0000000
Cost of Revenue175.00K303.00K395.00K519.00K52.00K58.00K58.00K46.00K
Gross Profit-175.00K-303.00K-395.00K-519.00K-52.00K-58.00K-58.00K-46.00K
Operating Expense28.39M37.20M29.44M35.43M14.14M38.02M24.15M23.07M
Operating Income-28.57M-37.50M-29.83M-35.95M-14.19M-38.08M-24.20M-23.12M
EBITDA-28.20M-36.73M-29.44M-35.43M-7.64M-34.19M-13.64M-28.09M
Net Income-28.38M-37.04M-27.53M-35.82M-7.82M-34.36M-13.70M-29.56M
R&D22.97M30.58M20.96M18.90M8.35M15.86M14.48M15.23M
Interest Expense--143.00K126.00K132.00K110.00K01.42M

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets17.81M40.66M101.79M69.09M3.35M12.19M19.79M13.59M
Total Liabilities5.79M12.25M7.01M4.07M12.58M4.03M5.38M20.23M
Total Equity12.02M28.41M94.79M65.02M-9.23M8.16M14.41M-6.64M
Cash12.83M15.87M33.42M13.36M1.33M5.53M7.93M11.52M
Total Debt78.81M131.36M--5.36M--9.70M
Net Debt65.98M115.49M-33.42M-13.36M4.03M-5.53M-7.93M-1.82M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-28.22M-31.21M-32.06M-31.50M-11.76M-25.73M-21.15M-21.18M
Investing Cash Flow-1.46M-20.62M-42.56M10.75M-4.00K8.88M-4.42M9.55M
Financing Cash Flow42.02M54.87M92.17M695.00K8.48M20.90M27.97M15.21M
Capital Expenditure1.46M605.00K1.02M488.00K4.00K78.00K8.00K28.00K
Free Cash Flow-29.68M-31.82M-33.09M-31.99M-11.76M-25.81M-21.15M-21.21M
FCF to OCF105.18%101.94%103.19%101.55%100.03%100.30%100.04%100.13%

Earnings

Report DateSep 25, 2020Nov 12, 2020Mar 4, 2021May 12, 2021Aug 11, 2021Nov 11, 2021Mar 10, 2022May 10, 2022Aug 11, 2022Nov 10, 2022Mar 9, 2023May 12, 2023Aug 10, 2023Nov 9, 2023Mar 28, 2024May 13, 2024Aug 12, 2024Nov 13, 2024Mar 26, 2025May 14, 2025Aug 12, 2025Nov 12, 2025Mar 3, 2026May 12, 2026Aug 11, 2026Nov 11, 2026
EPS Estimate0.00-0.56-0.40-6.16-6.55-5.18-5.12-5.35-5.63-6.16-6.16-0.73-1.04-1.14-0.87-0.74-0.53-0.50-0.35-0.30-0.35-0.41-2.06-0.28-0.33-0.75
EPS Actual-0.78-2.52-1.38-7.56-5.04-5.32-5.74-6.72-5.32-6.44-6.44-3.41-1.11-0.82-0.230.01-0.36-0.50-1.22-0.36-0.40-0.52-3.450.30-0.45-
Surprise--350.00%-245.00%-22.73%23.05%-2.70%-12.11%-25.61%5.51%-4.55%-4.55%-367.12%-6.73%28.07%73.56%101.35%32.08%0.00%-246.10%-20.00%-14.29%-26.83%-67.27%207.14%-36.36%-
TimingAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-market-

Key Statistics & Ratios

Market Cap11.95M
Enterprise Value2.81M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book2.22
EPS-6.91
Book Value0.897
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-19.59M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-365.70%
Return on Assets-63.58%
Shares Outstanding6.83M
Shares Float3.79M
Beta1.01
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 4 analystsTarget 50.00
  • Strong Buy
    3
  • Buy
    1

Ownership Breakdown

Institutions
57.51%
Insiders
18.53%
Retail / Other
23.96%

Top Institutional Holders

  • Squadron Capital Management LLC
    1.24M3.65%
  • Jane Street Group LLC
    178.51K0.52%
  • Vanguard Capital Management, LLC
    169.11K0.50%
  • Renaissance Technologies Corp
    128.07K0.38%
  • Geode Capital Management, LLC
    123.38K0.36%
  • 180 WEALTH ADVISORS, LLC
    83.40K0.24%
  • CAMBRIDGE Invest RESEARCH ADVISORS, INC.
    60.00K0.18%
  • Stonehage Fleming Financial Services Holdings Ltd
    53.70K0.16%
  • Vanguard Fiduciary Trust Co
    45.83K0.13%
  • HRT FINANCIAL LLC
    39.70K0.12%
  • Susquehanna International Group, LLP
    30.72K0.09%
  • Virtu Financial LLC
    17.89K0.05%
  • GSA Capital Partners LLP
    17.47K0.05%
  • State Street Corp
    17.07K0.05%
  • TritonPoint Partners, LLC
    15.12K0.04%
  • First Manhattan Co. LLC
    13.23K0.04%
  • SIMPLEX TRADING, LLC
    12.82K0.04%

Top Fund Holders

  • Abante Quant Value FI
    68.69K0.20%
  • Fidelity Extended Market Index
    50.08K0.15%
  • Fidelity Nasdaq Composite Index
    16.35K0.05%

Stock Splits

  • Aug 31, 20261:5